Fortis Therapeutics Closes $40 Million Series A Financing to Advance Novel Anti-CD46 Therapeutic to Treat Late-Stage Prostate Cancer and Multiple Myeloma
Retrieved on:
Monday, March 29, 2021
Research, FDA, Genetics, Clinical trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Clinical medicine, Medical specialties, Medicine, Immunology, Antineoplastic drugs, Biotechnology, MCRPC, Antibody-drug conjugate, CD46, Multiple myeloma, Prostate cancer, Cancer immunotherapy, Research, FDA, Genetics, Clinical trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Clinical medicine, Medical specialties, Medicine, Immunology, Antineoplastic drugs, Biotechnology, MCRPC, Antibody-drug conjugate, CD46, Multiple myeloma, Prostate cancer, Cancer immunotherapy, FOR46, Fortis Therapeutics
Fortis Therapeutics, Inc. , an immuno-oncology biotech developing FOR46, a novel antibody drug conjugate (ADC) against CD46, today announced the close of a $40 million Series A financing.
Key Points:
- Fortis Therapeutics, Inc. , an immuno-oncology biotech developing FOR46, a novel antibody drug conjugate (ADC) against CD46, today announced the close of a $40 million Series A financing.
- The proceeds of the financing will be used to advance FOR46 in clinical trials for the treatment of relapsed or refractory multiple myeloma and metastatic castration-resistant prostate cancer (mCRPC).
- Our preliminary clinical data is very exciting, and we are actively advancing our clinical studies in prostate cancer and multiple myeloma and pursuing additional indications.
- Fortis Therapeutics is an immuno-oncology biotech developing a novel antibody-drug conjugate for late-stage multiple myeloma and metastatic castration-resistant prostate cancer.